ISOTRETINOIN: FACTS AND CONTRADICTIONS
DOI:
https://doi.org/10.37547/Keywords:
acne, isotretinoin, treatment, dosage, side effectsAbstract
Summary Acne is one of the most common skin diseases that leads to persistent stigmatization and negatively affects the quality of life of patients. Currently, there are many treatments for this disease, but isotretinoin is the most effective against severe forms of acne and those cases where other forms of therapy have failed. Isotretinoin is an oral retinoid that has been used in clinical practice for about 40 years. This drug affects all the key links in the pathogenesis of acne, which determines its high effectiveness. Many clinical studies have been devoted to the study of the mechanisms of action of this drug, the specifics of its purpose, and undesirable side effects. Nevertheless, today, both patients and doctors have a number of misconceptions about the use of isotretinoin, which raises concerns about its administration, errors in treatment tactics, and low adherence to treatment. This article discusses the main issues about the mechanisms of action of isotretinoin, the specifics of its administration, indications and contraindications for use, undesirable side effects and ways to correct them, as well as the contradictions in the tactics of prescribing this drug that prevent its effective use. Special attention is paid to choosing the optimal therapeutic dose of isotretinoin and the duration of the course of treatment. In addition, the article discusses the main factors leading to failures in systemic retinoid therapy: slowing the onset of clinical response, the development of relapses after treatment, among which are the features of the course of the disease, the patient's age, his hormonal background, as well as the specifics of the dosage of the drug and the duration of its administration.
Downloads
References
1. Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bullach AGM. Patten S8. Efficacy and adverse events of oral isotretinoin for acne: a sys- stable remission.J Eur Acod Dermato! Venereol. 2011;25(9).1094-1098. https://doi.org/10.1111/j.1468-3083.2010.03933.x.
tematic review. Br J Dermatol. 2018:178(1):76-85. https://doiorg/101111/ 21. De D, Karwar AJ. Combination of low-dose isotretinoin and pulsed oral Diebaba aeletomgcin an ie meresemert or motrate to sevete che. a pretmn' Chernysher oy.Tomas-AradonesManolacheSvengsana.Marron S٤. Evers AWM et al. Which acne treatment has the best influence on health- relatea cuauer or Wier Leracure review dy the european Acacemy of Dermatolagy and Venerology Task Force on Quality of Life and Patient Oriented Outcomes. / Eur Acod Dermatol Venereol. 2018;32(9) 1410-1419. https://doi.org/10.1111/jdv.15048.
Costa CS, Bagatin E, Martimbianco ALC, da Silva EM, Lúcio MM, Magin P.l 2018;11(11) CD009435. https://dai.org/10.1002/14651858.CD009435.pub2 Drug Investig. 2011,31(8)599-604. https://doi.org/10.2165/1153957D-
LEBUU-BULUU 22. Ballanger F, Baudry P, N'Guyen JM, Khammari A, Dréno B. Heredity: a prog- nostic factor for acne. Dermatology. 2006;212(2).145-149. https://doi.org/
10.1159/000090655. 23. Rademaker M, Wishart JM, Birchall NM. Isotretinoin 5 mg daily for low- aeol csene uss -oseocotece aniomizo coube blind study. J Eur Acod Dermatol Venereol. 2014;28(6):747-754. macokinetics and therapeutic value. Methods Enzymol 1990190:291-304. https://doi.org/10.1016/0076-6879(90)90034-x. Colburn WA, Gibson DM, Wiens RE, Hanigan II. Food increases the bioavail- ability of isotretinoin. / Clin Pharmacol. 1983;23(11-12):534-539. https://doi.org/10.1002/j.1552-4604.1983.tb01800.x welstet , Lerden d, Gress i compuratve pramiacokinetk pronles ot a nain formulation: a randomized, 4-treatment, crossover study / Am Acod derHiate 2013071>1.402-ro1.nas//dctorg 1UaULدهeلحل.د.لء م3o Wiegand UW, Chou RC. Pharmacokinetics of oral isotretinoin. J Am Acod Dermatol. 1998;39(2 Pt 3):58-S12. https://doi.org/10.1016/10190 9622（98）70438-4.
8. Nelson AM, Gilliland KL, Cang Z, Thiboutoe DM. 13-cis Retinoic acid induc- Dermatol. 2006;126(10)2178-2189. https://doi.org/10.1038/sjjid5700289 SnE G, LIdO PT, CaE AL, PiAd, enang Mr, LI S/ el al Poxus ennances diller-
entiation and apoptosis in human primary keratinocytes. Exp Dermatol.
2018:27(11)1254-1260. https://doi.org/10.1111/exd.13775.
10. Rademaker M. Making sense of the effects of the cumulative dosel of isotretinoin in acne vulgaris. Int / Dermatol. 2016;55(5)-518-523. https://doi.org/10.1111/ljd.12942.
11. Norris UA, Usbarn k, Kobenson Vi, fonnesen Ma. Isatretinoin produces sigi niicancinnbiio, ar monoche ano feutoon chemotaxs myo in patients with cystic acne. / Invest Dermatol. 1987;89(1) 38-43. https//0o10r0/1U.1111/1523-1/47epl23803/u
12. Papakonstantinou E, Aletras AJ, Glass E, Tsoqas P, Dionyssopoulos A, Adjaye 1 et al. Matrix metalloproteinases of epithelial origin in facial sebum |
of patients with acne and their reculation by isctretinoin / Invest Dermatol.
2005;125(4)673-684. https://doi.orq/10.1111/j.0022-202X.2005.23848×
13. Zaenglein AL, Pathy AL, Schlosser Bl, Alikhan A, Baldwin HE, Berson DS et al. Guidelines of care for the management of acne vulgaris. / Am Acod Dermatol. 2016;74(5)945-973. hetps://doi.org/10.1016/jjaad 2015.12.037.
14. Altman EM. Isotretinoin and pregnancy prevention: do we need to take a long, hard look at oursetves? JAMA Dermatol. 2014;150(4) 361-362. httos:/doi.orc/10.100//amadermatol.20136975
15. Spierings NM, Natkunarajah J, Bansal A, Ostlere L Should we be prescrib- ino isotretinoin to patients with peanut allergies
